Company intelligence / Profile preview
Boundless Bio
San Diego, California, United Statesboundlessbio.com ↗
- Ownership
- Public · BOLD
- Employees
- ~72
- Development stage
- Phase 1
01
Overview
Currently conducting Phase 1/2 POTENTIATE trial for BBI-355 (CHK1 inhibitor) in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025. Recently discontinued development of BBI-825 due to pharmacokinetic concerns.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesoral inhibitorsoral degraders
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $54.8M
- Total revenue
- $0
- Enterprise value
- $-17.8M
Beyond the preview
Go deeper on Boundless Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boundless Bio.